Sanders Questioned FDA Nominee on Drug Pricing Claims
Senator Bernie Sanders pressed Dr. Heidi Overton regarding the accuracy of claims that the U.S. has the world's lowest prices.
Updated on Sept. 24, 2026 in Healthcare
Live Poll
Do you trust that your prescription drug costs are lower due to recent government policies?
During her Senate confirmation hearing, FDA nominee Dr. Heidi Overton faced questions from Senator Bernie Sanders about President Trump's assertions regarding prescription drug costs. The exchange centered on the accuracy of claims that the United States possesses the lowest drug prices globally.
Why it matters
The hearing highlights ongoing political scrutiny over whether domestic prescription drug costs truly lead the world in affordability. Senator Sanders sought to verify the administration's claims against international pricing benchmarks as part of the confirmation process.
Official data shows an 89% agreement rate among branded drug manufacturers to lower prices. Additionally, the Consumer Price Index recorded a 3% decrease in drug costs, a margin not seen in 60 years.
The players
Bernie Sanders
He is a United States Senator from Vermont who frequently focuses on healthcare policy and pharmaceutical pricing.
Heidi Overton
She is the FDA nominee who has previously served as deputy assistant to the president for domestic policy.
Donald Trump
He is the current President of the United States who has made public claims regarding the competitiveness of American prescription drug prices.
RAND Corporation
It is a research organization that provides analysis on public policy, including international healthcare cost comparisons.
The details
Dr. Heidi Overton, who has served as deputy assistant to the president for domestic policy since 2025, defended administration efforts by pointing to most favored nation policies. The discussion also noted that the RAND Corporation has identified lower prescription drug pricing structures in nations such as France and Japan.
Timeline
The Inflation Reduction Act was signed into law in 2022.
Dr. Heidi Overton began her role as domestic policy assistant in 2025.
The Senate confirmation hearing took place on Thursday.
This report was published on September 24, 2026.
Market Landscape
This confirmation hearing occurs as federal regulators work under the framework of the Medicare-negotiated prescription drug pricing provisions that took effect this year. The administration's focus on drug costs represents a continued attempt to shift market dynamics relative to global peers like France and Japan.
Consumers may see changes in prescription drug accessibility as 89% of branded drug manufacturers have signed agreements to lower prices. These policy shifts impact household budgets by adjusting the total cost of medication for those navigating the healthcare system.
The takeaway
The scrutiny of these pricing claims underscores the challenge of aligning domestic policy rhetoric with international drug cost benchmarks. Readers should monitor ongoing manufacturer compliance as the implementation of newer pricing agreements continues to evolve.
Further reading
For more context on ongoing industry policy, visit the Healthcare section.
More information
Review the latest updates on current policies at the Trump administration drug pricing portal.
Live Poll
Do you trust that your prescription drug costs are lower due to recent government policies?
